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INTRODUCTION
21st	century	is	a	promising	century,	after	the	explosion	
of	biosciences	and	medicine.	The	impact	of	new	fields	
of	medicine	such	as	molecular	medicine	and	molecu-
lar	pharmacology	is	associated	with	the	technological	
improvement.	Novel	techniques	borrowed	by	molecu-
lar	biology’s	«wisdom»	encouraged	scientists	to	find	
the	correlations	between	membrane	receptors	and	dis-
eases.	Molecular	pharmacology	 research	 in	 the	field	
of	diseases	associated	with	receptors	abnormalities	is	
still	going	on.	This	new	area	 in	 the	field	of	molecu-
lar	pharmacology	and	therapeutics	is	under	the	name	
«channelopathies».
Τhe	 question	 that	 arises	whether	migraine	 is	 an-
other	 channelopathy	 or	 an	 ion	 channel	 abnormality.	
Migraine	 is	 a	 heterogeneous	 neurovascular	 disorder	
that	has	a	strong	genetic	and	molecular	background.	It	
is	a	global	disorder	that	attacks	mostly	women	and	af-
fects	approximately	the	12%	of	the	general	population	
with	a	peak	in	reproductive	years	(22nd	until	55th	year	
of	 life)1-4.	The	International	Headache	Society	(HIS)	
classifies	migraine	into	two	subtypes:	migraine	with-
out	 aura	 (MO)	 characterized	 by	 photophobia	 and/or	
phonophobia,	emesis,	nausea	and	migraine	with	aura	
(MA)	with	additional	neurological	symptoms	includ-
ing	visual	disturbances	(blurring,	spots)1,4-.	In	order	to	
diagnose	MO,	five	attacks	are	needed	(in	4-2	hours)	
to	be	reported.	MA	is	divided	into	typical	aura,	spo-
radic	aura,	familiar	hemiplegic	migraine	(FHM)	and	
basilar-type	migraine4.
The	management	of	migraine	can	be	divided	into	
two	axes:	pharmacological	and	non	pharmacological	
intervention8,9.	 Research	 in	 laboratory	 animal	 mod-
els	(knockout	mice)	and	patients	suffering	especially	
from	 MA	 (associated	 with	 migraine	 family	 history	
background)	resulted	 in	 the	concept	 that	migraine	 is	
closely	related	to	receptor	abnormalities.	Consequent-
ly,	pharmacological	intervention	must	be	focused	on	
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receptors	in	order	to	find	the	right	treatment	scheme.	
However,	much	has	to	be	done	in	order	to	clarify	the	
molecular	mechanisms	behind	the	drug	-	receptor	in-
teraction	 and	 the	 therapeutic	 value	 of	 each	drug	 for	
migraine.	Recent	studies	revealed	a	 large	number	of	
important	 receptors	 that	 are	 involved	 in	 the	 patho-
physiology	of	migraine.	The	list	of	potential	new	drug	
targets	 for	migraine	 therapy	 is	continuously	updated	
and	 the	 need	 to	 identify	 the	molecular	mechanisms	
behind	migraine	is	vital.
PATHOPHYSIOLOGY OF MIGRAINE
Migraine	is	a	form	of	sensory	processing	disturbance	
with	wide	interactions	within	the	CNS10.	The	trigemi-
nal	system	-	the	sensory	system	of	the	brain	-	is	a	pain	
transmitting	 link	 from	 the	 cranial	 vasculature	 to	 the	
CNS11.	Changes	in	the	environmental	and	the	psycho-
logical	state	seem	to	initiate	an	abnormal	excitation	of	
the	primary	 intracranial	pain	fibres	or	-in	a	different	
version-	a	cortical	spreading	depression10,11.
The	action	potential	created	by	 the	abnormal	ex-
citation	 causes	 the	 release	 of	 glutamate	 and	 CGRP	
(calcitonin	gene-related	peptide)	which	results	in	the	
activation	of	second-order	neurones	in	the	trigeminal	
nucleus	 caudalis	 (TNC)	 and	 the	 upper	 two	 dimen-
sions	of	the	cervical	spinal	cord.	TNC	neurones	relay	
the	pain	signals	to	central	pain	processing	structures.	
Together	with	CGRP	there	 is	also	secretion	of	other	
vasoactive	neuropeptides	 [e.g.	 substance	P	 (SP),	va-
soactive	intestinal	peptide	(VIP)]	from	the	peripheral	
nerve	 endings.	As	 a	 consequence	 of	 the	 release	 of	
CGRP	mainly	there	is	meningeal	vasodilation,	plasma	
extravasation	and	mast	cell	degranulation	with	secre-
tion	of	other	proinflammatory	substances	in	the	dura	
matter	 causing	 neurogenic	 inflammation10,12.	 This	
type	of	inflammation	sensitizes	neurones	in	the	dorsal	
horn	 resulting	 in	 an	 increased	 response	 to	mechani-
cal	stimulation	of	receptive	fields	and	to	mechanical	
and	thermal	stimulation	of	cuteneous	receptive	fields.	
Their	response	thresholds	decrease	and	their	response	
magnitude	 increases.	This	may	 explain	 the	 intracra-
nial	and	extracranial	sensory	hypersensitivity	reported	
by	 the	patients11.	CGRP	enhances	and	maintains	 the	
activation	of	 second-order	neurones	and	 is	 the	main	
cause	of	the	pain	symptoms10.	Nausea	and	diarrhoea	
that	often	accompany	migraine	must	be	due	to	the	re-
lease	of	VIP	whose	secretion	initiates	these	autonomic	
symptoms13.
Cortical	spreading	depression	(CSD)	is	character-
ised	by	a	wave	of	depolarisation	and	causes	hypoae-
mia.	Scientists	have	found	that	CSD	may	lie	behind	
the	genesis	of	migraine’s	aura	but	there	is	no	verifica-
tion	yet	that	the	same	thing	happens	in	common	mi-
graine13.	 Laboratory	 investigation	 indicates	 reduced	
threshold	and	increased	velocity	of	CSD	resulting	in	
higher	susceptibility,	in	cortical	hyperexcitability	and	
link	spreading	depression	and	aura	in	migraine11.
THE SEROTONIN (5-HT) RECEPTORS:  
THE KEY-PLAYER IN MIGRAINE
The	 significant	 role	of	 5-HT	 receptors	 in	 the	patho-
genesis	 of	migraine	 was	 first	 revealed	 with	 the	 use	
of	triptans	for	the	treatment	of	acute	migraine3.	Sero-
tonin,	their	neurotransmitter	is	localized	both	in	CNS	
and	peripheral	nervous	system	thus	implicating	their	
involvement	in	various	physiological	conditions	such	
as	 nociception,	 circadian	 rhythm,	 thermoregulation,	
memory,	 sexual	 behaviour	 and	 pathological	 such	 as	
psychiatric	diseases	(e.g.	depression,	anxiety)	and	mi-
graine.
With	the	aid	of	molecular	and	functional	criteria,	
scientists	have	divided	5-HT	receptors	in	seven	class-
es	with	the	subtypes	5-HT
1A,	1B,	1D,	1E,	1F
	being	present	in	
humans4.	5-HT
1
	receptors	are	coupled	to	a	G-protein	
through	which	they	negatively	regulate	the	activity	of	
adenylate	 cyclase.	Among	 these	 receptors	 firstly	 5-
HT
1B
	and	secondly	5-HT
1D
	and	5-HT
1F
	seem	to	have	a	
central	role	in	the	pathogenesis	of	migraine	possibly	
due	to	their	distribution14.	5-HT
1B
	receptors	are	locat-
ed	on	intracranial	blood	vessels	and	CNS	neurones,	5-
HT
1D
	on	CNS	neurones	and	trigeminal	nerve	endings	
and	5-HT
1F
	on	trigeminal	nerve	endings4.
With	 the	 method	 of	 autoradiography	 scientists	
have	described	the	distribution	of	the	binding	sites	of	
5-HT	receptors	 in	 the	basal	gaglia.	5-HT
1B
	receptors	
are	 found	both	 in	 serotonergic	 and	non-serotonergic	
neurones	and	they	may	function	as	auto-	and	hetero-re-
ceptors,	respectively.	When	they	act	as	auto-receptors	
they	mediate	the	release	of	serotonin.	When	they	act	
as	hetero-receptors	they	mediate	the	release	of	other	
neuropeptides,	such	as	acetylcholine.	They	have	also	
been	 characterised	 as	 terminal	 receptors	 controlling	
the	release	of	neurotransmitters	presynaptically14.
Neuropharmacological	 studies	 suggest	 that	 sero-
tonin	and	its	receptors	are	involved	at	different	levels	
in	 the	pathogenesis	of	migraine15.	Firstly,	5-HT	me-
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tabolism	 is	 disturbed	 in	 migraine	 patients.	 Clinical	
evidence	has	shown	a	significant	reduction	of	urinary	
and	platelet	5-HT	during	migraine	attacks14.	The	defi-
ciency	of	5-HT	reported	in	migraine	attacks	results	in	
increased	5-HT	synthesis	and	in	central	5-HT	receptor	
hypersensitivity,	probably	as	a	self-response1,14.
Triptans	 is	 a	 class	 of	 agents	 that	 are	 agonists	 of	
5-HT
1B.	 1D,	 1F
	 receptors.	 They	 oppose	 their	 vasodila-
tory	effects	 in	cranial	blood	vessels	during	migraine	
attacks	 by	 causing	 vasoconstriction1,15.	 Triptans	 are	
used	for	 the	 treatment	of	moderate	 to	severe	attacks	
of	 migraine13.	 Sumatriptan	 was	 the	 prototype	 drug	
of	this	class	but	it	was	soon	replaced	by	second	gen-
eration	triptans	including	naratriptan	and	rizatriptan.	
Even	 though	 sumatriptan	 acts	 selectively	 on	 5-HT
1
	
receptors	 in	 cranial	 blood	vessels,	 it	 also	 acts	 on	5-
HT
1
	receptors	located	in	the	peripheral	blood	vessels1.	
In	addition,	 it	was	shown	 through	clinical	 trials	 that	
it	was	only	slightly	more	effective	than	non-steroidal	
anti-inflammatory	drugs	which	are	frequently	used	for	
the	treatment	of	mild	migraine	attacks13.	The	second	
generation	 triptans	maintain	 their	efficacy	 for	a	 lon-
ger	period	of	time	in	comparison	to	sumatriptan	under	
continuous	use3.	Even	though	they	have	similar	phar-
macodynamic	properties	with	sumatriptan,	pharmaco-
kinetics	and	oral	bioavailability	are	improved.	Some	
times	they	present	longer	plasma	half-life.	Their	mode	
of	 action	 depends	 upon	 the	 receptor	 they	 stimulate.	
When	 they	 stimulate	 the	 vascular	 5-HT
1B
	 receptor,	
vasoconstriction	 of	 cranial	 blood	 vessels	 is	 caused.	
When	 they	act	on	5-HT
1D
	and/or	5-HT
1F
	presynapti-
cally	they	may	inhibit	dural	neurogenic	inflammation1.	
Triptans	may	also	modulate	the	activity	of	trigemino-
vascular	nociceptive	neurones	and	inhibit	central	pain	
transmission	 possibly	 through	 their	 combined	 effect	
on	5-HT
1B,	1D,	1F
	receptors1,.
The	dilemma	that	arises	with	triptans	is	that	their	
mechanism	of	action	which	is	important	in	migraine	
treatment,	vasoconstriction,	can	be	at	the	same	time	a	
main	drawback.	This	is	due	to	the	risk	of	cardiovascu-
lar	side	effects	such	as	uncontrolled	hypertension,	that	
can	be	fatal,	to	a	certain	category	of	patients3,13.	Fur-
thermore	 triptans	 have	 contradictions	which	 include	
uncontrolled	hypertension,	coronary	heart	disease	and	
pregnancy3.
DOPAMINE (DA) RECEPTORS:  
BEYOND MIGRAINE?
There	 have	 been	 recognized	 five	 different	 types	 of	
DA	receptors	 in	 the	human	nervous	 system	so	 far16.	
They	 are	 involved	 in	 various	 physiological	 func-
tions	 such	 as	 vasoregulation,	 nociception	 and	 auto-
nomic	responses1.	They	exert	their	function	through	
G-proteins	to	which	they	are	closely	connected16.	DA
2
	
receptors	that	are	widely	expressed	in	CNS	and	DA
1
	
receptors	the	most	abundant	DA	receptors	in	humans	
have	an	important	role	in	the	aetiology	of	migraine	as	
well	 as	 in	many	 psychiatric	 diseases.	DA
1
	 and	DA
2
	
receptors	 are	 also	 distributed	 in	 the	 cardiovascular	
system	and	kidneys	as	radioligand	binding	and	auto-
radiographic	studies	have	shown.	Migraine	sufferers	
show	 deficiency	 of	 presynaptic	 dopamine	 and	 com-
pensatory	hypersensitivity	of	DA	postsynaptic	recep-
tors.	The	hypersensitivity	results	in	a	lower	threshold	
for	DA	receptor	activation.	This	may	explain	clinical	
features	of	migraine	such	as	nausea,	vomiting,	irrita-
bility	and	yawning18.
The	significant	role	of	DA	receptors	in	migraine	is	
also	supported	by	the	fact	that	DA	antagonists	such	as	
droperidol	are	effectively	used	in	migraine	and	asso-
ciated	symptoms	treatment	and	that	DA	agonists	con-
tribute	to	the	prophylactic	treatment	of	the	disorder1.	
Droperidol	 is	 an	 in	vivo	antagonist	of	DA	receptors	
and	an	effective	antimigraine	agent	as	a	randomized	
controlled	 trial	 performed	 on	 more	 than	 300	 mi-
graineurs	has	 indicated9.	Side	effects	 though	include	
anxiety	and	akathesia	and	it	is	not	recommended	suit-
able	for	patients	with	Parkinson’s	disease9,19.
A NEW ERA IN MIGRAINE THERAPY: THE 
SIGNIFICANT BUT CONTROVERSIAL ROLE 
OF CALCITONIN GENE-RELATED PEPTIDE 
(CGRP) RECEPTOR
The	release	of	the	neurotransmitter	CGRP	and	its	in-
teraction	with	the	CGRP	receptors	seem	to	play	a	key	
role	 in	 the	pathophysiology	of	migraine.	CGRP	and	
its	receptors	are	extensively	present	in	the	central	and	
peripheral	 nervous	 system15.	More	 specifically,	 they	
are	widely	expressed	in	the	trigeminovascular	system,	
a	region	which	is	closely	associated	with	the	migraine	
headache1,15.
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CGRP	 receptors	 are	 involved	 in	 various	 patho-
physiological	functions	such	as	modulation	of	motor,	
sensory,	pain	pathways	and	tone	regulation	of	the	cra-
nial	blood	vessels15,20.	Under	the	guidance	of	molecular	
criteria	it	has	been	observed	that	there	are	two	types	of	
CGRP	receptors,	CGRP
1
	and	CGRP
2
.	CGRP
1
	recep-
tors	 appear	 to	 be	 highly	 abundant	 in	 humans.	Only	
three	of	the	components	comprising	the	CGRP
1
	recep-
tor	 complex	 are	 till	 now	 recognized.	Each	 one	 pos-
sesses	a	different	role:	(a)	the	calcitonin-like	receptor	
component	 (CLR),	 (b)	 the	 receptor	 activity-modify-
ing	protein-1	component	(RAMP-1)	and	(c)	the	recep-
tor	component	protein	(RCP)20,21.	Further	studies	need	
to	 be	 carried	 out	 regarding	 the	 complete	 molecular	
structure	of	CGRP
1
	receptor	in	order	to	reveal	all	its	
essential	components	and	thus	to	understand	how	they	
interact	each	other	and	exert	their	function.	CGRP
2
	re-
ceptors	haven’t	been	described	in	humans	yet21.
The	presence	of	CGRP
1
	receptors	in	humans	was	
first	 discovered	 in	 2002	 using	 its	 antagonist	 BIB-
N4096BS	(olcegepant)21.	The	preclinical	studies	that	
followed	concerning	migraine	began	to	change	direc-
tion.	 Further	 evidence	 was	 obtained	 in	 regard	 with	
intravenously	 administrated	 olcegepant	 and	 its	 anti-
migraine	 effect	 based	 on	 experiments	 performed	 on	
migraine	 patients.	 The	 reported	 relief	 of	 headache	
marked	at	that	point	the	quest	for	the	aetiopathologi-
cal	mechanisms	in	migraine9.
During	migraine	attacks	there	are	increased	plasma	
concentrations	of	CGRP	as	studies	in	vivo	and	in	vitro	
have	shown11,15.	This	observation	has	been	described	
both	 in	migraine	with	and	without	aura11.	CGRP	re-
lease	 seems	 to	 induce	 dilation	of	 cranial	 blood	ves-
sels	 in	migraine11,15.	CGRP	also	enhances	and	main-
tains	activation	of	second-order	neurones	which	cause	
the	pain	symptoms10.	Furthermore	the	level	of	CGRP	
plasma	 concentration	 seems	 to	 be	 closely	 related	 to	
the	severity	of	pain11.
CGRP	 antagonist	 (olcegepant)	 surpasses	 other	
antimigraine	agents	such	as	triptans	in	many	aspects.	
Experiments	performed	on	animals	have	shown	 that	
they	inhibit	the	action	of	stimulated	trigeminovascular	
neurones	by	avoiding	interference	with	the	cardiovas-
cular	 system	 that	 could	cause	vasoconstriction.	This	
indicates	that	vasoconstriction	isn’t	probably	the	«cor-
rect»	target	for	a	novel	antimigraine	agent.	In	addition	
the	CGRP	antagonist	acts	postsynaptically	implicating	
that	their	possible	combination	with	triptans	which	act	
presynaptically	can	be	very	beneficial10.	It	‘s	observed	
that	 CGRP
1
	 receptors	 represent	 highly	 promising	
therapeutic	 targets.	 Pharmacological	 studies	 are	 in	
search	for	the	development	of	an	orally	active	CGRP
1
	
antagonist	as	it	appears	to	be	one	of	the	most	effective	
antimigraine	emerging	therapies.
AN ENIGMA IN MIGRAINE:  
VANILLOID (VR-1 OR TRPV-1) RECEPTORS
During	the	last	decade	TRPV-1	receptor	drew	the	at-
tention	 as	 a	 possible	 effective	 therapeutic	 target	 in	
migraine.	 It	belongs	 to	 the	 family	of	«thermo	TRP»	
channels	and	experiments	in	knock-out	mice	revealed	
the	phenomenon	of	post-inflammatory	thermal	hyper-
algesia	that	it	causes22.	A	lot	of	trials	still	remain	to	be	
perfomed	in	order	to	light	its	mechanism	of	action	and	
to	determine	the	efficacy	and	side	effects	of	possible	
antagonists	in	the	treatment	of	migraine.
There	 are	 six	 subfamilies	 of	 TRPV	 receptors.	
Among	 them,	 TRPV-1	 receptor	 is	 an	 intramembra-
nous	 protein	which	 is	 present	 in	 small	 and	medium	
sized	neurones	in	dorsal	root	gaglia,	trigeminal	gaglia	
in	brainstem	and	in	several	non-neuronal	tissues9.	It	is	
involved	in	the	integration	of	painful	stimuli	by	taking	
part	in	the	transmission	of	nociceptive	signals	in	neu-
rogenic	inflammation22.	TRPV-2	receptor	is	present	in	
CNS	and	 expressed	 in	 aortic	myocytes,	TRPV-3	 re-
ceptor	is	found	in	keratinocytes	and	seems	to	act	as	a	
heat	sensor,	TRPV-4	receptor	functions	as	an	osmotic	
receptor	and	TRPV-5,6	receptors	seem	to	be	involved	
in	 vitamin	 D-dependent	 calcium	 uptake	 in	 kidneys	
and	intestine11,22.
TRPV-1	receptor	is	directly	activated	by	external	
and	internal	stimuli	such	as	high	temperatures,	low	pH,	
capsaicin	analogs	and	indirectly	by	liberating	the	re-
ceptor	from	PIP
2
	(phosphatidylinositol	bisphosphate)	
which	has	 an	 inhibitory	 effect9,11,22.	The	TRPV-1	 re-
ceptor	 is	 connected	with	 sodium	 and	 calcium	 chan-
nels	of	cellular	membrane	through	which	it	exerts	its	
function9.	It	is	suggested	that	it	may	promote	release	
of	 CGRP	 from	 trigeminal	 neurones	 in	 pathological	
conditions	such	as	migraine22.
Capsaicin	 is	 considered	 to	 be	 the	 best	 known	
vanilloid9.	It	is	a	compound	substance	extracted	from	
chilli	 pepper	 and	 stimulates	 the	TRPV-1	 receptor	 in	
primary	 sensory	 neurones22.	 Following	 stimulation,	
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pro-inflammatory	 neuropeptides	 such	 as	 CGRP	 are	
released	from	the	sensory	terminals	which	induce	the	
neurogenic	inflammation9,22.	The	activation	of	TRPV-
1	receptor	is	followed	rapidly	by	a	period	of	desensiti-
zation	during	which	anti-inflammatory	and	analgesic	
effects	take	place9,11,22.	At	this	stage	the	TRPV-1	recep-
tor	leaves	its	position	on	the	cell	membrane	and	moves	
to	intracellular	compartments	where	it	is	recycled.	The	
phenomenon	of	desensitization	is	of	great	advantage	
in	 the	 therapeutic	 strategies	 against	 migraine.	 Mo-
lecular	and	pharmacological	studies	are	now	focusing	
on	the	development	of	TRPV-1	antagonists	 that	will	
make	them	capable	of	being	administrated	systemati-
cally	in	contrast	to	capsaicin22.
OPIOID RECEPTORS AND MIGRAINE
Opioids	exist	in	natural	and	synthetic	form	and	act	via	
opioid	receptors	that	are	located	in	CNS	as	well	as	in	
the	peripheral	nerve	 terminals	and	digestive	 system.	
There	are	four	families	of	opioid	receptors	(μ,	κ,	δ,	σ).	
All	opioid	receptors,	through	their	connection	with	in-
hibitory	G-proteins,	inhibit	adenyle	cyclate.	They	also	
exert	their	function	through	ion	channels	resulting	in	
hyperpolarization	 and	neurotransmitter	 release.	Opi-
oids	bind	to	a	specific	site	on	the	receptor	promoting	
analgesic	and	anti-stress	effects	 that	mimic	 the	ones	
generated	by	the	action	of	endogenous	neuropeptides,	
the	opiopeptides19,23.
Opioids	can	be	effective	 in	 the	 treatment	of	pain	
in	migraine	patients15.	They	are	considered	as	rescue	
drugs	and	are	administrated	when	all	other	therapeu-
tic	strategies	lose	their	efficacy.	They	are	also	chosen	
among	other	antimigraine	drugs	for	pain	relief	in	preg-
nant	 migraine	 patients	 in	 the	 absence	 of	 controlled	
data4.	Their	adverse	effects	 (respiratory	suppression,	
addiction,	urinary	retention,	nausea,	vomiting,	consti-
pation)	mostly	arise	from	their	overuse	which	is	a	very	
frequent	phenomenon	due	to	their	euphoric	properties.	
Opioid	antagonists	have	an	important	clinical	role	in	
managing	opioid	overdose19,23.
GLUTAMATE RECEPTORS AND MIGRAINE
Glutamate	is	an	amino	acid	that	acts	upon	NMDA	(N-
methyl-D-aspartic	 acid)	 and	 non-NMDA	 receptors	
such	as	the	AMPA	(a-amino-3-hydroxy-5-methyloxa-
zole)	receptors	and	the	kainate	receptor.	Glutamate	is	
probably	the	most	significant	neurotransmitter	in	the	
thalamocortical	projections	and	cells	of	pyramid	sys-
tem16,23.	Glutamate	 receptors	are	also	widely	distrib-
uted	in	the	trigeminal	system.	They	have	an	excitatory	
effect	in	human	brain	and	seem	to	cause	hyperirrita-
bility15.	More	specifically,	noxious	stimulation	of	tri-
geminal	neurones	increases	the	cellular	concentration	
of	glutamate	and	excites	the	neurones	in	the	trigemi-
nal	nucleus	caudalis	 resulting	 in	cortical	hyperexcit-
ability,	typical	of	migraine9,15.
Glutamate	 and	 its	 receptors	 are	 being	 studied	 as	
possible	 antimigraine	 targets15.	 Genetic	 evidence	
seems	 to	 support	 the	 participation	 of	 glutamate	 and	
its	receptors	in	migraine	pathophysiology.	A	specific	
mutation	of	the	excitatory	amino	acid	transporter	ap-
pears	to	cause	postsynaptic	hyperexcitation	due	to	ac-
cumulation	of	glutamate	in	the	synaptic	cleft9.	Recent	
pharmacological	data	support	that	GluR5	(a	subunit	of	
kainate	 receptor)	 selective	 antagonists	 are	 clinically	
effective	in	certain	forms	of	allodynia	and	hyperalge-
sia,	as	well	as	acute	migraine.	This	brings	to	the	scene	
the	contribution	of	kainate	receptors	in	the	pathogen-
esis	of	migraine.	Kainate	receptors,	possibly	 located	
presynaptically,	are	future	pharmacological	targets	for	
novel	drugs	because	they	seem	to	regulate	GABA	and	
glutamate	release	in	bidirectional	way24.
CANNABINOID RECEPTORS
There	 haven’t	 been	 yet	 clinical	 studies	 that	 support	
the	use	of	cannabinoids	in	the	treatment	of	migraine.	
Cannabinoids	are	considered	as	important	blood	pres-
sure	lowering	agents.	This	pharmacological	property	
brings	forward	the	idea	of	using	them	in	decreasing	the	
risk	or/and	 the	 severity	of	migraine	crisis.	Although	
studies	conflict	about	the	clinical	use	of	cannabinoids	
in	 cardiovascular	 function,	 they	 remain	 a	new	pros-
pect	of	migraine	therapeutics25.
CONCLUSION
Through	 the	progress	achieved	 in	 the	understanding	
of	migraine	mechanisms,	 the	biomolecular	receptors	
seem	 to	 provide	 new	 insights	 into	 migraine	 treat-
ment,	as	 they	are	 involved	 in	migraine	pathogenesis	
extensively.	Molecular	and	genetic	studies	regarding	
migraine	are	focusing	now	on	the	development	of	ef-
fective	antimigraine	agents	that	will	be	able	to	act	not	
only	at	a	clinicopathological	stage	but	also	at	a	pre-
clinical	stage	prophyllacticaly.
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